Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ST101 in Alzheimer's Disease
NCT00842673Phase 2Completed
- Sponsor
- Sonexa Therapeutics
- Start
- Feb 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of lucicebtide in Alzheimer's disease (AD), sponsored by Sonexa Therapeutics. Started Feb 2009; status: completed.
02
Drugs
lucicebtide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00842673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00842673.